AU2020390288A1 - Antibodies to CD3 and BCMA, and bispecific binding proteins made therefrom - Google Patents

Antibodies to CD3 and BCMA, and bispecific binding proteins made therefrom Download PDF

Info

Publication number
AU2020390288A1
AU2020390288A1 AU2020390288A AU2020390288A AU2020390288A1 AU 2020390288 A1 AU2020390288 A1 AU 2020390288A1 AU 2020390288 A AU2020390288 A AU 2020390288A AU 2020390288 A AU2020390288 A AU 2020390288A AU 2020390288 A1 AU2020390288 A1 AU 2020390288A1
Authority
AU
Australia
Prior art keywords
seq
bcma
antibody
cancer
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020390288A
Other languages
English (en)
Inventor
Shiyong GONG
Lini HUANG
Zhengrong SHUAI
Chengbin Wu
Danqing WU
Xuan WU
Amin ZHANG
Rui Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Epimab Biotherapeutics Co Ltd
Original Assignee
Shanghai Epimab Biotherapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Epimab Biotherapeutics Co Ltd filed Critical Shanghai Epimab Biotherapeutics Co Ltd
Publication of AU2020390288A1 publication Critical patent/AU2020390288A1/en
Priority to AU2024278367A priority Critical patent/AU2024278367A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2020390288A 2019-11-26 2020-11-26 Antibodies to CD3 and BCMA, and bispecific binding proteins made therefrom Pending AU2020390288A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024278367A AU2024278367A1 (en) 2019-11-26 2024-12-12 Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/120991 2019-11-26
CN2019120991 2019-11-26
CN2020111796 2020-08-27
CNPCT/CN2020/111796 2020-08-27
PCT/CN2020/131767 WO2021104371A1 (en) 2019-11-26 2020-11-26 Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024278367A Division AU2024278367A1 (en) 2019-11-26 2024-12-12 Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Publications (1)

Publication Number Publication Date
AU2020390288A1 true AU2020390288A1 (en) 2022-05-26

Family

ID=76130007

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020390288A Pending AU2020390288A1 (en) 2019-11-26 2020-11-26 Antibodies to CD3 and BCMA, and bispecific binding proteins made therefrom
AU2024278367A Pending AU2024278367A1 (en) 2019-11-26 2024-12-12 Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024278367A Pending AU2024278367A1 (en) 2019-11-26 2024-12-12 Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Country Status (11)

Country Link
US (1) US20230002489A1 (https=)
EP (2) EP4483895A3 (https=)
JP (2) JP7773466B2 (https=)
KR (2) KR20240162588A (https=)
CN (1) CN114728065A (https=)
AU (2) AU2020390288A1 (https=)
CA (1) CA3160163A1 (https=)
IL (2) IL293138A (https=)
MX (2) MX2022006230A (https=)
TW (1) TWI774137B (https=)
WO (1) WO2021104371A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519251B2 (en) * 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
EP4200336A4 (en) * 2020-08-24 2024-09-25 Epimab Biotherapeutics (HK) Limited Anti-ror1 antibodies and related bispecific binding proteins
EP4413044A4 (en) * 2021-10-07 2025-10-22 Nat Res Council Canada ANTI-CD3 MONOCLONAL ANTIBODIES AND THERAPEUTIC CONSTRUCTS
CN117003871A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
TW202413405A (zh) * 2022-07-13 2024-04-01 美商翰森生物有限責任公司 抗體、其抗原結合片段及其藥物用途
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用
EP4640700A1 (en) * 2022-12-19 2025-10-29 Harbour Biomed (Shanghai) Co., Ltd "kappa/lambda" fab-fab series-connection multi-specific binding protein, preparation thereof, and use thereof
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117024596B (zh) * 2023-08-18 2024-02-27 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025131075A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3和抗cd3多特异性抗体及用途
WO2025168059A1 (zh) * 2024-02-08 2025-08-14 天劢源和生物医药（上海）有限公司 靶向bcma、cd19和cd3的多特异性抗原结合蛋白及其应用
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
KR101972446B1 (ko) * 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
WO2014122143A1 (en) * 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
IL263466B2 (en) * 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
US10519251B2 (en) * 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
TWI703159B (zh) * 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
EP3916018A1 (en) * 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
US11421028B2 (en) * 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
JP7033328B2 (ja) * 2016-08-16 2022-03-10 エピムアブ バイオセラピューティクス インコーポレイテッド 一価の非対称タンデムＦａｂ二重特異性抗体
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
KR102820804B1 (ko) * 2017-09-22 2025-06-16 우시 바이올로직스 아일랜드 리미티드 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체
JP2021508479A (ja) * 2017-12-27 2021-03-11 テネオバイオ， インコーポレイテッド ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン
EP3788079A4 (en) * 2018-05-03 2022-12-21 Shanghai Epimab Biotherapeutics Co., Ltd. ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF
UA130542C2 (uk) * 2018-05-16 2026-03-18 Янссен Байотек, Інк. Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта

Also Published As

Publication number Publication date
EP4065164A4 (en) 2024-03-27
TWI774137B (zh) 2022-08-11
JP2025011311A (ja) 2025-01-23
CN114728065A (zh) 2022-07-08
IL316618A (en) 2024-12-01
IL293138A (en) 2022-07-01
EP4483895A2 (en) 2025-01-01
WO2021104371A1 (en) 2021-06-03
MX2022006230A (es) 2022-06-22
KR20220104783A (ko) 2022-07-26
KR20240162588A (ko) 2024-11-15
AU2024278367A1 (en) 2025-01-09
JP7773466B2 (ja) 2025-11-19
EP4483895A3 (en) 2025-05-28
TW202132347A (zh) 2021-09-01
JP2023504016A (ja) 2023-02-01
US20230002489A1 (en) 2023-01-05
EP4065164A1 (en) 2022-10-05
JP7847630B2 (ja) 2026-04-17
CA3160163A1 (en) 2021-06-03
MX2024013229A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
WO2021104371A1 (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
US12325742B2 (en) Anti-mesothelin antibodies
US20250361312A1 (en) Fc binding fragments comprising an ox40 antigen-binding site
WO2022042488A1 (en) Anti-ror1 antibodies and related bispecific binding proteins
US12060425B2 (en) High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
WO2022258015A1 (en) Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
KR20250039519A (ko) 항-pd-1 항체-약화된 il-2 면역접합체 및 그의 용도
JP2021501583A (ja) 抗体および使用方法
RU2852663C1 (ru) Антитела против cd3 и bcma и биспецифичные связывающие белки, полученные из них
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
WO2022228545A1 (en) Antibodies and variants thereof against human 4-1bb
BR122025002178A2 (pt) Anticorpos para cd3 e bcma, e proteínas de ligação biespecíficas feitas a partir dos mesmos